Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis

Klimiuk, Piotr Adrian; Sierakowski, Stanisław; Latosiewicz, Robert; Cylwik, B; Skowroński, J; Chwiećko, Justyna

doi:10.1093/rheumatology/41.1.78

Cited by 70 publications

(69 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, this was observed with levels of serum MMP-3, and although it is disappointing that we did not demonstrate changes in levels of other biochemical markers with MTX therapy, the study was not designed to address this question and the number of patients receiving MTX was limited. Our findings regarding serum MMP-3 levels in patients treated with MTX are consistent with the results of other studies that have shown a decrease in circulating MMP-3 levels with conventional DMARD therapy (43,44) or biologic therapy (45)(46)(47).…”

Section: Young-min Et Alsupporting

confidence: 92%

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers

Young-Min¹,

Cawston²,

Marshall³

et al. 2007

Arthritis & Rheumatism

113

View full text Add to dashboard Cite

Objective. To evaluate the performance of biochemical and traditional markers in predicting radiographic progression in rheumatoid arthritis (RA).Methods. One hundred thirty-two patients with early RA were treated with nonbiologic therapies for 2 years and studied longitudinally. Genomic DNA was analyzed for presence of the shared epitope. Conclusion. These results indicate that biochemical markers are useful predictors of radiographic progression in RA and that serum MMP-3 levels decrease significantly with MTX therapy. Multivariate models that include MMP-3 and CTX-II perform better than existing traditional markers in predicting radiographic outcome in RA.

show abstract

Section: Young-min Et Alsupporting

confidence: 92%

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers

Young-Min¹,

Cawston²,

Marshall³

et al. 2007

Arthritis & Rheumatism

113

View full text Add to dashboard Cite

show abstract

“…Association of the MMP-1-MMP-3 loci with disease activity Previous studies have shown significant correlations of MMP-1, and particularly MMP-3 serum levels with levels of inflammation in RA. 7,[9][10][11][13][14][15] In this study, we found significant correlations of MMP-1 and MMP-3 with the level of disease activity (DAS28 at baseline Figure 2 Relationship between MMP genotypes and circulating levels of MMPs. Panels (a-d) show serum levels of MMP-1 in patients with different genotypes of rs1799750, rs495366, rs679620 and rs3025058, respectively.…”

Section: Association Of Mmp-1-mmp-3 Loci With Circulating Levels Of Mmpsmentioning

confidence: 75%

“…Elevated levels of MMP-1 and -3 have been observed in patients with RA in both serum and synovial fluid, and are strongly associated with inflammation and joint destruction. [6][7][8][9][10][11][12][13][14][15][16][17][18][19] The genes for MMP-1 and -3 are both located on the long arm of chromosome 11, in a cluster together with seven other MMP members including MMP-7, -8, -10, -12 and -13. In recent years, functionally relevant and phenotype associated polymorphisms have been detected across the region of both genes.…”

Section: Introductionmentioning

confidence: 99%

“…Serum levels of MMP-1, and MMP-3 in particular, have been considered to be a useful markers of inflammation in RA, 7,[9][10][11][13][14][15] and have been shown to be predictive of joint destruction in early RA as well as reflecting ongoing joint damage in established RA. [11][12][13]15 In this study, we provide the most detailed analysis to date of the genotypic and haplotypic relationships of the MMP-1 and -3 genes with circulating levels of these MMPs in RA, and have investigated whether polymorphisms at these loci are associated with the level of disease activity over time.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of variations across the MMP-1 and -3 genes on the serum levels of MMP-1 and -3 and disease activity in rheumatoid arthritis

Chen

Nixon²,

Dawes³

et al. 2011

Genes Immun

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) are involved in joint destruction in rheumatoid arthritis (RA), and are strongly associated with levels of inflammation. To understand the relationship between MMP-1 and -3 variants and MMP levels in RA, we investigated the genotypic and haplotypic relationships of the MMP-1 and -3 genes with circulating levels of these MMPs. The genotypes of single-nucleotide polymorphisms (SNPs) rs1799750 (1G/2G, MMP-1 promoter), rs495366 (G/A, intergene), rs679620 (A/G, MMP-3 coding region) and rs3025058 (5A/6A, MMP-3 promoter) were determined in 430 RA patients. Each polymorphism was associated with serum levels of MMP-1 (P trend o0.0001 for each SNP), with haplotype 1G-G-A-5A associated with the highest level. The intergenic and MMP-3 SNPs were associated with MMP-1 levels independent of the MMP-1 promoter SNP. The MMP-3 SNPs were associated with serum MMP-3 level (P trend o0.0001 for each SNP), and were each associated with mean time-averaged disease activity (DAS28) in patients followed up for 2 years (P ¼ 0.003). Our findings indicate that several closely linked polymorphisms in the MMP-1-MMP-3 loci have an important role in determining the circulating levels of these MMPs in RA, and that MMP-3 polymorphism is associated with the level of disease activity over time.

show abstract

“…Elevated serum levels of MMPs have been reported in, for example, polycystic kidney disease (19), systemic sclerosis (20), rheumatoid arthritis (21), and cancer. In some diseases, such as acute viral hepatitis, however, serum levels of MMPs are reduced (22).…”

mentioning

confidence: 99%

High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1 Are Associated with Rapid Progression in Patients with Metastatic Melanoma

Nikkola

Vihinen

Vuoristo

et al. 2005

Clinical Cancer Research

169

127

View full text Add to dashboard Cite

Purpose: Matrix metalloproteinases (MMP) are proteolytic enzymes that play an important role in various aspects of cancer progression. In the present work, we have studied the prognostic significance of serum levels of gelatinase B (MMP-9), collagenase-1 (MMP-1), and collagenase-3 (MMP-13) in patients with advanced melanoma. Experimental Design: Total pretreatment serum levels of MMP-9 in 71patients and MMP-1and MMP-13 in 48 patients were determined by an assay system based on ELISA. Total MMP levels were also assessed in eight healthy controls. The active and latent forms of MMPs were defined by usingWestern blot analysis and gelatin zymography. Results: Patients with high serum levels of MMP-9 (z376.6 ng/mL; n = 19) had significantly poorer overall survival (OS) than patients with lower serum MMP-9 levels (n = 52; median OS, 29.1 versus 45.2 months; P = 0.033). High MMP-9 levels were also associated with visceral or bone metastasis (P = 0.027), elevated serum alkaline phosphatase level (P = 0.0009), and presence of liver metastases (P = 0.032). Serum levels of MMP-1and MMP-13 did not correlate with OS. MMP-1 and MMP-9 were found mainly in latent forms in serum, whereas the majority of MMP-13 in serum was active (48 kDa) form. MMP-13 was found more often in active form in patients (mean, 99% of the total MMP-13 level) than in controls (mean, 84% of the total MMP-13 level; P < 0.0001). After initiating the therapy, patients with elevated levels of MMP-1 (z29.8 ng/mL, n = 10) progressed more rapidly than patients with lower levels (median, 1.9 versus 3.5 months; P = 0.023). Serum levels of MMP-9 and MMP-13 did not correlate with the time to progression (TTP). In multivariate analysis with age and gender, MMP-9 or MMP-1turned out to be independent prognostic factors for OS [P = 0.039; hazard ratio (HR), 1.8; 95% confidence interval (95% CI), 1.03-3.3] or TTP (P = 0.023; HR, 2.7; 95% CI, 1.15-6.4), respectively. Conclusions: Our findings provide evidence that MMP-1, MMP-9, and MMP-13 play important roles at different phases of metastatic melanoma spread and that serum MMP-9, in particular, could have clinical value in identifying patients at high risk for melanoma progression.

show abstract

Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis

Cited by 70 publications

References 35 publications

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers

Influence of variations across the MMP-1 and -3 genes on the serum levels of MMP-1 and -3 and disease activity in rheumatoid arthritis

High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1 Are Associated with Rapid Progression in Patients with Metastatic Melanoma

Contact Info

Product

Resources

About